EICHOR
● Suspended
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Condition: Solid Tumors · Sponsor: Boehringer Ingelheim
About this study
This study is open to adults with different types of advanced cancer (solid tumors) that are accessible for injection and/or biopsy. This is a study for people with a life expectancy of at least 3 months after starting study treatment. The purpose of this study is to find the highest dose of a medicine called BI 1831169 that people with advanced cancer can tolerate when taken with or without a type of antibody called a checkpoint inhibitor (anti-PD-1 antibody). Another purpose is to check whether the study treatment can fight cancer. In this study, BI 1831169 is given to people for the first time. This study has 2 parts. In Part 1, participants get BI 1831169 alone for up to 3 months. In Part 2, participants get BI 1831169 in combination with a checkpoint inhibitor. Participants who take the combination treatment get BI 1831169 for up to 3 months and a checkpoint inhibitor for up to 1 year. BI 1831169 is given as an injection into the tumor, or as an infusion into the vein, or both (injection and infusion). Checkpoint inhibitors are given as an infusion into a vein. Participants get the medicines about every 3 weeks. This is called a treatment cycle. Participants visit the site study site regularly. The number of study visits vary based on the study phase and treatment response. Some visits include an overnight stay. The doctors regularly check the participants' health and monitor the tumors. The doctors also take note of any health problems that could have been caused by t…
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (27)
| Banner MD Anderson Cancer Center-Gilbert-55251 | Gilbert, Arizona, United States | — |
| University of Arizona | Tucson, Arizona, United States | — |
| University of California San Diego | La Jolla, California, United States | — |
| Providence St. John's Health Center | Santa Monica, California, United States | — |
| University of Colorado Denver | Aurora, Colorado, United States | — |
| Orlando Health Cancer Institute | Orlando, Florida, United States | — |
| M Health Fairview University of Minnesota Medical Center | Minneapolis, Minnesota, United States | — |
| Morristown Medical Center | Morristown, New Jersey, United States | — |
| Atrium Health Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem, North Carolina, United States | — |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | — |
| Peninsula Haematology & Oncology | Frankston, Victoria, Australia | — |
| Medical University of Innsbruck | Innsbruck, Austria | — |
+ 15 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05155332